These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 7963811

  • 41. Establishment and characterization of an acquired cisplatin-resistant subline in a human osteosarcoma cell line.
    Asada N, Tsuchiya H, Ueda Y, Tomita K.
    Anticancer Res; 1998; 18(3A):1765-8. PubMed ID: 9673402
    [Abstract] [Full Text] [Related]

  • 42. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer.
    Lorusso D, Petrelli F, Coinu A, Raspagliesi F, Barni S.
    Gynecol Oncol; 2014 Apr; 133(1):117-23. PubMed ID: 24486604
    [Abstract] [Full Text] [Related]

  • 43. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
    Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG.
    Cancer Res; 1992 Dec 15; 52(24):6885-9. PubMed ID: 1458477
    [Abstract] [Full Text] [Related]

  • 44. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer.
    De Andrés L, Brunet J, López-Pousa A, Burgués J, Vega M, Tabernero JM, Mesía R, López JJ.
    J Clin Oncol; 1995 Jun 15; 13(6):1493-500. PubMed ID: 7751897
    [Abstract] [Full Text] [Related]

  • 45. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
    Peng B, Tilby MJ, English MW, Price L, Pearson AD, Boddy AV, Newell DR.
    Br J Cancer; 1997 Jun 15; 76(11):1466-73. PubMed ID: 9400943
    [Abstract] [Full Text] [Related]

  • 46. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
    Alvarez-Valdés A, Pérez JM, López-Solera I, Lannegrand R, Continente JM, Amo-Ochoa P, Camazón MJ, Solans X, Font-Bardía M, Navarro-Ranninger C.
    J Med Chem; 2002 Apr 25; 45(9):1835-44. PubMed ID: 11960495
    [Abstract] [Full Text] [Related]

  • 47. [Cost-effectiveness analysis comparing carboplatin and weekly paclitaxel with cisplatin and docetaxel in the treatment of advanced non-small cell lung carcinoma].
    Inage S, Ise Y, Obayashi M, Katayama S, Gemma A.
    Gan To Kagaku Ryoho; 2010 Nov 25; 37(11):2093-100. PubMed ID: 21084806
    [Abstract] [Full Text] [Related]

  • 48. A Bayesian dosing method for carboplatin given by continuous infusion for 120 h.
    Guillet P, Monjanel S, Nicoara A, Duffaud F, Lacarelle B, Bagarry-Liegey D, Durand A, Catalin J, Favre R.
    Cancer Chemother Pharmacol; 1997 Nov 25; 40(2):143-9. PubMed ID: 9182836
    [Abstract] [Full Text] [Related]

  • 49. Nephrotoxicity of cisplatin, carboplatin and transplatin. A comparative in vitro study.
    Hannemann J, Baumann K.
    Arch Toxicol; 1990 Nov 25; 64(5):393-400. PubMed ID: 2169720
    [Abstract] [Full Text] [Related]

  • 50. [Pharmacokinetics of carboplatin after intraperitoneal administration and clinical effect in ovarian cancer].
    Ohno M, Hirokawa M, Hando T.
    Gan To Kagaku Ryoho; 1992 Dec 25; 19(14):2355-61. PubMed ID: 1463342
    [Abstract] [Full Text] [Related]

  • 51. In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines.
    Perez RP, Perez KM, Handel LM, Hamilton TC.
    Cancer Chemother Pharmacol; 1992 Dec 25; 29(6):430-4. PubMed ID: 1568285
    [Abstract] [Full Text] [Related]

  • 52. Therapeutic efficacy of long duration-low temperature whole body hyperthermia when combined with tumor necrosis factor and carboplatin in rats.
    Sakaguchi Y, Makino M, Kaneko T, Stephens LC, Strebel FR, Danhauser LL, Jenkins GN, Bull JM.
    Cancer Res; 1994 Apr 15; 54(8):2223-7. PubMed ID: 8174130
    [Abstract] [Full Text] [Related]

  • 53. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
    Jones M, Siracky J, Kelland LR, Harrap KR.
    Br J Cancer; 1993 Jan 15; 67(1):24-9. PubMed ID: 8427780
    [Abstract] [Full Text] [Related]

  • 54. Effect of hyperthermia on the action of cis-diamminedichloroplatinum(II), rhodamine 123(2) [tetrachloroplatinum(II)], rhodamine 123, and potassium tetrachloroplatinate in vitro and in vivo.
    Herman TS, Teicher BA, Chan V, Collins LS, Kaufmann ME, Loh C.
    Cancer Res; 1988 May 01; 48(9):2335-41. PubMed ID: 3356001
    [Abstract] [Full Text] [Related]

  • 55. Platinum complex-induced dysfunction of cultured renal proximal tubule cells. A comparative study of carboplatin and transplatin with cisplatin.
    Courjault F, Leroy D, Coquery L, Toutain H.
    Arch Toxicol; 1993 May 01; 67(5):338-46. PubMed ID: 8396390
    [Abstract] [Full Text] [Related]

  • 56. Definition of a physiologic pharmacokinetic model of cutaneous drug distribution using the isolated perfused porcine skin flap.
    Williams PL, Riviere JE.
    J Pharm Sci; 1989 Jul 01; 78(7):550-5. PubMed ID: 2674404
    [Abstract] [Full Text] [Related]

  • 57. Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo.
    Kusumoto T, Holden SA, Ara G, Teicher BA.
    Int J Hyperthermia; 1995 Jul 01; 11(4):575-86. PubMed ID: 7594810
    [Abstract] [Full Text] [Related]

  • 58. Effects of pre-heating on cis-diamminedichloroplatinum(II)-hyperthermia-induced tumour growth depression of transplantable human oesophageal cancer to nude mice.
    Yano T, Nakatani K, Watanabe A, Nakano H, Ohnishi T.
    Int J Hyperthermia; 1993 Jul 01; 9(5):699-708. PubMed ID: 8245581
    [Abstract] [Full Text] [Related]

  • 59. [Intraperitoneal and intrathoracic administration of hydroxyapatite-carboplatin (HAp-CBDCA)].
    Mohri N, Mizuno I, Akamo Y, Takeyama H, Manabe T.
    Gan To Kagaku Ryoho; 1999 Oct 01; 26(12):1791-3. PubMed ID: 10560396
    [Abstract] [Full Text] [Related]

  • 60. Evaluation for Synergistic Effects by Combinations of Photodynamic Therapy (PDT) with Temoporfin (mTHPC) and Pt(II) Complexes Carboplatin, Cisplatin or Oxaliplatin in a Set of Five Human Cancer Cell Lines.
    Lange C, Bednarski PJ.
    Int J Mol Sci; 2018 Oct 16; 19(10):. PubMed ID: 30332729
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.